The CRISPR system provides adaptive immunity against mobile genetic elements in bacteria and archaea. On detection of viral RNA, type III CRISPR systems generate a cyclic oligoadenylate (cOA) second messenger 1-3 , activating defence enzymes and sculpting a powerful antiviral response that can drive viruses to extinction 4,5 . Cyclic nucleotides are increasingly implicated as playing an important role in host-pathogen interactions 6,7 . Here, we identify a widespread new family of viral anti-CRISPR (Acr) enzymes that rapidly degrade cyclic tetra-adenylate (cA4). The viral ring nuclease (AcrIII-1) is the first Acr described for type III CRISPR systems and is widely distributed in archaeal and bacterial viruses, and proviruses. The enzyme uses a novel fold to bind cA4 specifically and utilizes a conserved active site to rapidly cleave the signalling molecule, allowing viruses to neutralise the type III CRISPR defence system. The AcrIII-1 family has a broad host range as it targets cA4 signalling molecules rather than specific CRISPR effector proteins. This study highlights the crucial role of cyclic nucleotide signalling in the conflict between viruses and their hosts.
Hereafter we propose the collective name AcrIII-1 for this family, as it is the first Acr described for type III systems and is not specific for an individual subtype of the type III effectors 28 .
To explore the mechanism of the AcrIII-1 family, we cloned and expressed two family members in E. coli: the SIRV1 gp29 protein and the YddF protein encoded by an integrative and conjugative element ICEBs1 from B. subtilis 29 . Both proteins possess a potent ring nuclease activity, rapidly degrading cA4 to generate linear di-adenylate (ApA>P) with a cyclic 2',3' phosphate ( Figure 2 and extended data figure 3 ). With a catalytic rate exceeding 5 min -1 , the anti-CRISPR enzyme is at least 60-fold more active than the cellular ring nuclease Crn1 from S. solfataricus. We showed previously that the type III-D CRISPR effector of S. solfataricus generates cA4 in proportion to the amount of cognate target RNA present 16 . By varying target RNA input and following cA4 levels and Csx1 activity, we compared the abilities of Crn1 and AcrIII-1 to destroy the signalling molecule and deactivate the ancillary defence nuclease Csx1. In keeping with its low turnover number, the Crn1 enzyme was effective at degrading cA4 and thus deactivating Csx1 only at the lowest levels of target RNA (Figure 3a) . In contrast, AcrIII-1 degraded cA4 completely at the highest target RNA concentration examined, preventing Csx1 activation. To provide a more rigorous test, we examined the ability of both enzymes to prevent Csx1 activation over a range of cA4 concentrations spanning four orders of magnitude ( Figure 3b ). Crn1 (2 µM) provided protection only up to 5 µM cA4, but in contrast 2 µM AcrIII-1 provided complete protection at the highest level of cA4 tested (500 µM). Thus, AcrIII-1 has the potential to destroy large concentrations of the cA4 second messenger rapidly, negating the immune response.
Several apo-structures for AcrIII-1 family members are available, revealing a dimeric protein of novel fold 22, 23, 30 . Importantly, this structure is completely unrelated to the CRISPR associated Rossman fold (CARF) domain, which is the only protein family thus far known to bind cOA 11 . To elucidate the mechanism of cA4 binding and cleavage by AcrIII-1, we co-crystallised an inactive variant (H47A) of SIRV1 gp29 with cA4 and solved the structure to 1.55 Å resolution (Figure 4) . The complex reveals a molecule of cA4 bound at the dimer interface. Comparison of the cA4-bound and apo structures reveals a significant movement of a loop, comprising residues 82-94, and subsequent a-helix, to bury cA4 within the dimer. These loops adopt variable or unstructured conformations in the various apo protein structures 22, 23, 30 . Once bound, the ligand is completely enclosed by the protein -a considerable accomplishment when one considers the large size of the ligand and the small size of the protein (Figure 4b ). By can neutralise the type III-B system in S. islandicus. Replicative plasmids with (pOE-gp29) or without (pOE) gp29 were transformed into the S. islandicus RJW007∆type I-A mutant, and the resulting strains were then challenged with SSeV. Plaques are only observed on the lawn of the strain expressing gp29. Data are representative of three biological replicates. (b) Schematic showing the recombinant M. tuberculosis type III-A CRISPR interference system established in E. coli. By swapping the native Csm6 ancillary nuclease for a Csx1 protein, the system can be converted from cA6 to cA4-mediated immunity. (c) Plasmid transformation assay using a plasmid with a match to a spacer in the CRISPR array. If the plasmid is successfully targeted by the CRISPR system, transformants will not be seen. Plasmids with or without the duf1874 gene are targeted successfully when cA6 (Csm6) mediated antiviral signalling is active. In contrast, cells using a cA4-based (Csx1) system only prevent transformation when the DUF1874 protein is not present, showing that the protein is effective in neutralising cA4-based CRISPR interference. The controls lack cOA-dependent ribonucleases.
Figure 2. AcrIII-1 rapidly degrades cA4 to linear products (a)
Single-turnover kinetic analysis of cyclic tetra-adenylate (cA4, 200 nM) degradation by AcrIII-1 SIRV1 gp29 (4 µM dimer, 50 °C), showing rapid generation of A2>P (di-adenylate with a 2',3'-cyclic phosphate) via an A4>P intermediate visualised by phosphorimaging following thin-layer chromatography. A2>P is further hydrolysed to A2-P (di-adenylate with a 3' phosphate). Each lane corresponds to reaction quenched at 5 second intervals up to 1 min, and then at 1.25, 1.5, 3, 6 and 12 min. Control reaction (cA4 cntrl) is cA4 incubated in the absence of protein for 12 min at 50 °C. (b) Liquid chromatography-high resolution mass spectrometry analysis confirms that AcrIII-1 SIRV1 gp29 converts cA4 (top panel) to A2>P within 2 min which is then converted to A2-P (bottom panel). (c) Kinetic comparison of cA4 degradation by the AcrIII-1 enzymes SIRV1 gp29 (4 µM dimer, 50 °C) and YddF (8 µM dimer, 37 °C) with the Crn1 enzyme Sso2081 (4 µM dimer, 50°C). Data were quantified and plotted to show the fraction of cA4 cut over time and fitted to an exponential equation, as previously described 8 . For YddF and Crn1 the data shown is the average of three independent experiments and for SIRV1 gp29 the data is the average of two biological replicates comprising three independent replicates for each. The error indicated is the standard deviation of the mean.
superimposing the cA4 ligand on the apo-protein structure, it becomes apparent that the binding site is largely pre-formed, with the exception of the mobile loops that form the lid (Figure 4c ). The overall change is like two cupped hands catching a ball, with the loops (fingers) subsequently closing around it.
The cA4 molecule makes symmetrical interactions with each monomer of AcrIII-1 (Extended data figure 4 ). Upon binding of cA4, arginine R85 on the loop from one monomer interacts with the distant half of the cA4 molecule and appears to 'lock' the closed dimer. Other important interactions are made with main chain L92, I69, and N8, and side chains R66, N8, Q81, S11, T50, S49, and N13, most of which are semi or fully conserved (Extended data figure 1 & 5), suggesting they have important roles in cA4 binding and/or catalysis in this whole family of enzymes.
At two positions, on opposite sides of the ring, the 2'-hydroxyl of the ribose is positioned correctly for in-line attack on the phosphodiester bond, consistent with the observed bilateral cleavage ( Figure 4d ). The catalytic power of the AcrIII-1 family likely derives from active site residues that position the 2'-hydroxyl group for in-line nucleophilic attack, stabilise the transition state and protonate the oxyanion leaving group 31 . For the AcrIII-1 family, the absolutely conserved residue His-47 is suitably positioned to act as a general acid and fulfil the latter role ( Figure 4d ). To test this hypothesis, we assayed variant H47A of AcrIII-1. The variant enzyme suffered a >2500-fold decrease in catalytic power, which could be partially reversed by chemical rescue with 500 mM imidazole in the reaction buffer (Extended data figure 6 ).
By targeting a key signalling molecule, a single AcrIII-1 enzyme should have broad utility in the inhibition of endogenous type III CRISPR systems in any species. The only constraint is the specificity for the cA4 signalling molecule. Of the CRISPR ancillary nucleases studied to date, most are activated by cA4; activation by cA6 appears to be limited to certain bacterial phyla including the Firmicutes and Actinobacteria 10 . By targeting the cA4 activator, AcrIII-1 will neutralize a slew of defence enzymes simultaneously. For example, Thermus thermophilus has two Csm6 enzymes 32,33 and a recently described DNA nuclease, Can1 34 . All are activated by cA4 and would thus be deactivated by AcrIII-1. Recently, two other Acr proteins with enzymatic functions have been described: AcrVA1 which catalyses crRNA cleavage of Cas12a 35 and AcrVA5, which acetylates the PAM-sensing site of Cas12a 36 . Both, however, target a protein (or protein:nucleic acid complex), implying a requirement for specific interactions that could be evaded by sequence variation.
The gene encoding AcrIII-1 is most prominent in the archaeal viruses, where it is found in representatives of at least five distinct viral families, making it one of the most widely conserved of all archaeal virus proteins 30 (Extended data figure 1). Within archaeal genomes, homologues are typically adjacent to ORFs from mobile genetic elements rather than CRISPR loci, a good example being the STIV virus integrated into S. acidocaldarius genomes 37 . The distribution of AcrIII-1 in archaea is sporadic but covers most of the lineages, including crenarchaea, euryarchaea, thaumarchaea, Asgard archaea and others. AcrIII-1 is also present in several bacteriophages of the order Caudovirales, and there are many instances of acrIII-1 genes in sequenced bacterial genomes, with homologues found in the Firmicutes, cyanobacteria, proteobacteria, actinobacteria and many more. Maximum likelihood phylogenetic analysis of the AcrIII-1 proteins suggests multiple horizontal gene transfers between unrelated viruses as well as between bacteria and archaea (Extended data figure 7 ). Sometimes the acrIII-1 gene is clearly part of an integrated mobile genetic element as is the case for the yddF gene in B. subtilis 30 . However, in other species (n=49) the gene is associated with cellular type Figure 3 . AcrIII-1 neutralises cA4-activated CRISPR defence enzyme Csx1 (a) Top panel is a phosphor image of denaturing PAGE visualising activation of Csx1 (0.5 "M dimer) in a coupled assay containing type III Csm complex when activated with indicated amounts of (unlabeled) target RNA to initiate cA4 synthesis. Each set of three lanes after the control (c) reaction with Csx1 and substrate RNA alone, is first in the absence and then with AcrIII-1 SIRV1 gp29 (2 "M dimer) or Crn1 Sso2081 (2 "M dimer), respectively. Whereas AcrIII-1 degraded all cA4 generated with up to 50 nM RNA target, the Crn1 enzyme deactivated Csx1 only when less than 5 nM RNA target was used to initiate cA4 synthesis. The lower panel is a phosphorimage of TLC with reactions as above but visualises cA4 production, by α-ATP incorporation, and degradation, in the presence of indicated amounts of RNA target and absence or presence of either AcrIII-1 or Crn1, and is representative of the results of three independent experiments. Csx1 deactivation correlates with complete cA4 degradation. (b) Denaturing PAGE showing activation of Csx1 (0.5 "M dimer) by indicated amounts (500-0.5 "M) of HPLCpurified cA4 and its subsequent deactivation when either AcrIII-1 or Crn1 (2 "M dimer) was present to degrade cA4. The AcrIII-1 enzyme degraded 100-fold more cA4 than Crn1. Control reaction (c) shows RNA incubated with Csx1 in the absence of cA4. The image is representative of the results of three independent experiments. III CRISPR systems (Extended data figures 7-9). In Marinitoga piezophilia, AcrIII-1 is fused to a cOA-activated HEPN ribonuclease of the Csx1 family. Since both active sites are conserved, this fusion protein may have cA4 activated ribonuclease activity coupled with a cA4 degradative ring nuclease, thus providing an explicit linkage between the AcrIII-1 family and the type III CRISPR system. In this context the enzyme is likely acting as a host-encoded ring nuclease, like Crn1, rather than an Acr. We therefore propose the family name of Crn2 (CRISPR associated ring nuclease 2) to cover DUF1874 family members that are associated with type III CRISPR systems.
AcrIII-1 is the first Acr have functional roles in both viruses and cells 38 . It remains to be determined whether the acrIII-1 gene arose in viruses and was appropriated by cellular type III systems or vice versa. However, the extremely broad distribution of acrIII-1 and limited distribution of crn2 suggests the former. Adoption of an anti-CRISPR protein as a component of a cellular CRISPR defence system seems counter-intuitive. However, the enzyme could be harnessed for a role in defence by either "detuning" its activity to make it a slower enzyme, or by putting it under tight transcriptional control so that it is expressed at very low levels. The unprecedented wide occurrence of this Acr across many archaeal and bacterial virus families reflects the fact that this enzyme degrades a key signalling molecule to subvert cellular immunity. This makes it very hard for cells to evolve counterresistance, other than by switching to a different signalling molecule. The recent discovery of multiple cyclic nucleotide signalling systems in bacteria may thus reflect the ongoing conflict between cells and viruses. 
METHODS

Construction of S. islandicus strains
The type I-A CRISPR defence module including seven genes i.e. cas3b, csa5, cas7, cas5, cas3', cas3', and casX 39 was in-frame deleted from the genetic host S. islandicus RJW007, derived from wild-type strain S. islandicus M.16.4 carrying a double pyrEF and argD deletion 26 , by employing Plasmid Integration and Segregation knockout strategy 40 . The type I-A deletion mutants were confirmed by PCR using primers that bind outside of the homologous flanking arms.
Synthesised SIRV1 gp29 gene was purchased from IDT as a g-block and was cloned into a Sulfolobus-E.coli shuttle vector pSeSd-SsoargD 26 (referred to as pOE hereafter) at the NdeI and NotI sites, generating the gp29 expression plasmid pOE-gp29 in which the gp29 gene was placed under the control of the arabinose promoter. The pOE-gp29 and pOE plasmids were then transformed into competent cells of the ∆type I-A mutant via electroporation as described previously 26 , generating strains expressing and not expressing SIRV1 gp29, respectively.
Viral quantification
To calculate the titer of SSeV, 100 µL diluted virus (10 -5 , 10 -6 , and 10 -7 ) was co-incubated with 500 µL S. islandicus Y08.82.36 host 27 (10-fold concentrated) without shaking at 76-78 °C for 30 min. Afterwards, the virus-infected cells were transferred into a glass test tube containing 5 mL of pre-warmed Sucrose-Yeast (SY) and 0.8% gelrite mixture, and plated onto SY plates. The plates were put into a plastic bag, and incubated for two days at 76-78 °C. Plaques were counted in plates with proper virus dilutions, and the titer of SSeV were determined as 4.96×10 8 plaque forming units (PFU) per ml.
Infection by virus SSeV of S. islandicus M.16.4 with a type III CRISPR defence
The SSeV infection assay was carried out according to the procedure as described previously 41 with minor modifications. In brief, approximately 6 × 10 8 cells of RJW007∆type I-A/pOE and RJW007∆type I-A/pOE-gp29 taken from the exponential stage were spun down at 4000 rpm × 12 min, and resuspended in 1mL of Arabinose-Tryptone (AT) medium. The resuspensions were then co-incubated with 20 mL of fresh AT medium or SSeV supernatant at different dilutions (10 0 , 10 -1 , 10 -2 , 10 -3 , 10 -4 , 10 -5 , and 10 -6 ) in a Falcon tube at 76-78 °C for 1 h without shaking. The SSeV-infected cells were washed twice with 10 mL of AT medium and resuspended into 500 µL of AT medium. Afterwards, the concentrated SSeV-infected cells were mixed with 5 mL of top layer (2.5 mL of 2×Arabinose-Yeast medium+2.5 mL of 0.8% gelrite), and then plated onto the Arabinose-Yeast plates. PFU were counted after 4 days of incubation at 76-78 °C. Three independent experiments were performed.
Cloning and purification
For cloning, synthetic genes (g-blocks) were purchased from Integrated DNA Technologies (IDT), Coralville, USA, and cloned into the vector pEhisV5spacerTev between the NcoI and BamHI sites 8 . Competent DH5a (Escherichia coli) cells were transformed with the construct and sequence integrity confirmed by sequencing (Eurofins Genomics). The plasmid was transformed into Escherichia coli C43 (DE3) cells for protein expression. Cloning of AcrIII-1 SIRV1 gp29, Crn1 Sso2081 and SsoCsx1 has been previously described 16, 22 . For expression of SIRV1 gp29 and Bacillus subtilis YddF, 2 L of Luria-Broth culture was grown at 37 °C to an OD600 of 0.8 with shaking at 180 rpm. Protein expression was induced with 0.4 mM Isopropyl β-D-1-thiogalactopyranoside and cells were grown at 25 °C overnight before harvesting by centrifugation at 4000 rpm (Beckman Coulter Avanti JXN-26; JLA8.1 rotor) at 4 °C for 15 min.
For protein purification the cell pellet was resuspended in four volumes equivalent of lysis buffer containing 50 mM Tris-HCl 7.5, 0.5 M NaCl, 10 mM imidazole and 10% glycerol supplemented with EDTA-free protease inhibitor tablets (Roche; 1 tablet per 100 ml buffer) and lysozyme (1 mg/ml). Cells were lysed by sonicating six times 1 min with 1 min rest intervals on ice at 4 °C, and the lysate was ultracentrifuged at 40,000 rpm (70 Ti rotor) at 4 °C for 35 min. The lysate was then loaded onto a 5 ml HisTrap FF Crude column (GE Healthcare) equilibrated with wash buffer containing 50 mM Tris-HCl pH 7.5, 0.5 M NaCl, 30 mM imidazole and 10% glycerol. Unbound protein was washed away with 20 column volumes (CV) of wash buffer prior to elution of his-tagged protein using a linear gradient (holding at 10% for 3 CV, and 50% for 3 CV) of elution buffer containing 50 mM Tris-HCl pH 7.5, 0.5 M NaCl, 0.5 M imidazole and 10% glycerol. SDS-PAGE was carried out to identify fractions containing the protein of interest, and relevant fractions were pooled and concentrated using a 10 kDa molecular weight cut-off centrifugal concentrator (Merck). The his-tag was removed by incubating concentrated protein overnight with Tobacco Etch Virus (TEV) protease (1 mg per 10 mg protein) while dialysing in buffer containing 50 mM Tris-HCl pH 7.5, 0.5 M NaCl, 30 mM imidazole and 10% glycerol at room temperature. The protein with his-tag removed was isolated using a 5 ml HisTrapFF column, eluting the protein using 4 CV wash buffer. His-tag removed protein was further purified by size-exclusion chromatography (S200 16/60; GE Healthcare) in buffer containing 20 mM Tris-HCl pH 7.5, 0.125 M NaCl using an isocratic gradient. After SDS-PAGE, fractions containing protein of interest were concentrated and protein was aliquoted and stored at -80 °C. Variant enzymes were generated using the QuickChange Site-Directed Mutagenesis kit as per manufacturer's instructions (Agilent technologies) and purified as for the wild-type proteins.
Radiolabelled cA4 cleavage assays
Cyclic oligoadenylate (cOA) was generated by incubating 120 µg Sulfolobus solfataricus (Sso) type III-D (Csm) complex with 5 nM a-32 P-ATP, 1 mM ATP, 120 nM A26 RNA target and 2 mM MgCl2 in Csx1 buffer containing 20 mM 2-(Nmorpholino)ethanesulfonic acid (MES) pH 5.5, 100 mM K-glutamate, 1 mM DTT and 3 units SUPERase•In™ Inhibitor for 2 h at 70 °C in a 100 µl reaction volume. cOA was extracted by phenol-chloroform (Ambion) extraction followed by chloroform extraction (Sigma-Aldrich), and stored at -20 °C.
For single turnover kinetics experiments AcrIII-1 SIRV1 gp29 and variants (4 "M protein dimer) were assayed for radiolabelled cA 4 degradation by incubating with 1/400 diluted 32 P-labelled SsoCsm cOA (~200 nM cA4; when generated in a 100 "l cOA synthesis reaction as described above) in Csx1 buffer supplemented with 1 mM EDTA at 50 °C. AcrIII-1 YddF (8 "M dimer) was incubated with cOA in buffer containing 20 mM MES pH 6.0, 100 mM NaCl, 1 mM DTT, 1 mM EDTA and 3 units SUPERase•In™ Inhibitor at 37 °C. For SIRV1 gp29 H47A chemical rescue, reactions were supplemented with 0.5 M imidazole. Two experimenters were involved in kinetic experiments involving 5 s time points. At desired time points, a 10 "l aliquot of the reaction was removed and quenched by adding to phenol-chloroform and vortexing. Subsequently, 5 "l of deproteinised reaction product was extracted into 5 "l 100% formamide xylene-cyanol loading dye if intended for denaturing polyacrylamide gel electrophoresis (PAGE), or products were further isolated by chloroform extraction if intended for thin-layer chromatography (TLC). A reaction incubating cOA in buffer without protein to the endpoint of each experiment was included as a negative control. All experiments were carried out in triplicate. For SIRV1 gp29 two biological samples were assayed in triplicate. cA 4 degradation was visualised by phosphor imaging following denaturing PAGE (7M urea, 20% acrylamide, 1x TBE) or TLC.
For TLC, 1 µl of radiolabelled product was spotted 1 cm from the bottom of a 20 x 20 cm silica gel TLC plate (Supelco Sigma-Aldrich). The TLC plate was placed in a sealed glass chamber pre-warmed and humidified at 37 °C and containing 0.5 cm of a running buffer composed of 30% H 2 O, 70% ethanol and 0.2 M ammonium bicarbonate, pH 9.2. The temperature was lowered to 35 °C and the buffer was allowed to rise along the plate through capillary action until the migration front reached 17 cm. The plate was air dried and sample migration was visualised by phosphor imaging.
For kinetic analysis, cA4 cleavage was quantified using the Bio-Formats plugin 42 of ImageJ as distributed in the Fiji package 43 and fitted to a single exponential curve (y = m1 + m2*(1 -exp(-m3*x));m1=0.1;m2=1;m3=1;) using Kaleidagraph (Synergy Software), as described previously 44 . The cA4 cleavge rate by the H47A variant in the absence of imidazole was obtained by linear fit.
Deactivation of HEPN nucleases by ring nucleases in coupled assays
In the absence and presence of Crn1 Sso2081 (2 "M dimer) or AcrIII-1 SIRV1 gp29 (2 "M dimer) 4 "g S. solfataricus Csm complex (~140 nM Csm carrying crRNA targeting A26 RNA target) was incubated with A26 RNA target (50, 20, 5, 2, or 0.5 nM) in buffer containing 20 mM MES pH 6.0, 100 mM NaCl, 1 mM DTT and 3 units SUPERase•In™ Inhibitor supplemented with 2 mM MgCl 2 and 0.5 mM ATP at 70 °C for 60 min. 5'-end 32 P-labelled A1 RNA (AGGGUAUUAUUUGUUUGUUUCUUCUAAACUAUAAGCUAGUUCUGGAGA) and 0.5 "M dimer SsoCsx1 was added to the reaction at 60 min and the reaction was allowed to proceed for a further 60 min before quenching by adding phenol-chloroform. A1 RNA cleavage was visualised by phosphor imaging after denaturing PAGE. A control reaction incubating SsoCsx1 with A1 RNA in the absence of cOA was carried out to determine SsoCsx1 background activity. cA4 synthesis by Csm in response to A26 RNA target and subsequent cA4 degradation in the presence of Crn1 Sso2081 or AcrIII-1 SIRV1 gp29, was visualised by adding 5 nM a-32 P-ATP with 0.5 mM ATP at the start of the reaction. Reactions were quenched at 60 min with phenol-chloroform and cA4 degradation products were visualised by phosphor imaging following TLC. A control reaction incubating Csm with ATP and a-32 P-ATP in the absence of A26 RNA target was also carried out, quenching the reaction after 60 min. cA4 degradation capacity of AcrIII-1 SIRV1 gp29 versus the Crn1 enzyme (Sso2081) was determined by incubating 2 "M dimer of each enzyme with 500-0.5 "M unlabelled cA4 (BIOLOG Life Science Institute, Bremen, Germany) in Csx1 buffer at 70 °C for 20 min before introducing SsoCsx1 (0.5 "M dimer) and 32 P-labelled A1 RNA (50 nM). The reaction was left to proceed for a further 60 min at 70 °C before quenching by adding phenol-chloroform. Deproteinised products were separated by denaturing PAGE to visualise RNA degradation.
Plasmid transformation assays
Tsac 2833 mediated plasmid immunity from a reprogrammed type III system in E. coliPlasmids pCsm1-5_ DCsm6 (containing the type III Csm interference genes cas10, csm3, csm4, csm5 from M. tuberculosis and csm2 from M. canettii), pCRISPR_TetR (containing M. tuberculosis cas6 and tetracycline resistance gene-targeting CRISPR array), pRAT-Target (tetracyclineresistance, target plasmid) and M. tuberculosis (Mtb)Csm6/ Thioalkalivibrio sulfidiphilus (Tsu)Csx1 expression constructs have been described previously 10 . pRAT-Duet was constructed by replacing the pUC19 lacZa gene of pRAT-Target with the MCSs of pACYCDuet-1 by restriction digest (5'-NcoI, 3'-XhoI). The viral ring nuclease (duf1784) gene from Thermoanaerobacterium phage THSA_485A, tsac_2833, was PCR-amplified from its pEHisTEV expression construct and cloned into the 5'-NdeI, 3'-XhoI sites of MCS-2. The cOA-dependent nucleases (mtb csm6, tsu csx1) were cloned into the 5'-NcoI, 3'-SalI sites of MCS-1 by restriction digest from their respective expression constructs. Each nuclease was cloned with and without the viral ring nuclease; pRAT-Duet without insert and pRAT-Duet containing only the viral ring nuclease were used as controls. The plasmid transformation assay was carried out essentially as described in 10 . E. coli C43 containing pCsm1-5_DCsm6 and pCRISPR_TetR were transformed by heat shock with 100 ng of pRAT-Duet target plasmid containing different combinations of cOA-dependent nuclease and viral ring nuclease. After outgrowth at 37 °C for 2 h, cells were collected and resuspended in 200 µl LB. A series of 10-fold dilutions was applied onto LB agar containing 100 µg ml -1 ampicillin and 50 µg ml -1 spectinomycin to determine the cell density of the recipient cells and onto LB agar additionally containing 25 µg ml -1 tetracycline, 0.2% (w/v) D-lactose and 0.2% (w/v) L-arabinose to determine the cell density of viable transformants. Plates were incubated at 37 °C for 16 -18 h; further incubation was carried out at room temperature.
Liquid chromatography high-resolution mass spectrometry
AcrIII-1 SIRV1 gp29 (40 "M dimer) was incubated with 400 "M cA4 in Csx1 buffer for 2 min at 70 °C and deproteinised by phenol-chloroform extraction followed by chloroform extraction. Liquid chromatography-high resolution mass spectrometry (LC-HRMS) analysis was performed on a Thermo Scientific™ Velos Pro instrument equipped with HESI source and Dionex UltiMate 3000 chromatography system. Compounds were separated on a Kinetex® EVO C18 column (2.6 µm, 2.1 ´ 50 mm, Phenomenex) using the following gradient of acetonitrile (B) against 20 mM ammonium bicarbonate (A): 0 -2 min 2% B, 2 -10 min 2 -8% B, 10 -11 min 8 -95% B, 11 -14 min 95% B, 14 -15 min 95 -2% B, 15 -20 min 2% B at a flow rate of 300 µl min -1 and column temperature of 40 °C. UV data were recorded at 254 nm. Mass data were acquired on the FT mass analyzer in negative ion mode with scan range m/z 150 -1500 at a resolution of 30,000. Source voltage was set to 3.5 kV, capillary temperature was 350 °C, and source heater temperature was 250 °C. Data were analysed using Xcalibur™ (Thermo Scientific).
Phylogenetic analysis
AcrIII-1 homologs were collected by using gp29 (NP_666617) of SIRV1 as a query and running two iterations (E=1e-05) of PSI-BLAST 45 against the non-redundant protein database at NCBI. The sequences were aligned using PROMALS3D 46 . Redundant sequences (95% identity threshold) and sequences with mutated H47 active site residue were removed from the alignment. Poorly aligned (low information content) positions were removed using the gt 0.2 function of Trimal 47 . The final alignment contained 124 positions. The maximum likelihood phylogenetic tree was constructed using the PhyML program 48 with the automatic selection of the best-fit substitution model for a given alignment. The best model identified by PhyML was LG +G+I. The branch support was assessed using aBayes implemented in PhyML. The tree was visualized using iTOL 49 .
Crystallisation
AcrIII-1 H47A variant was concentrated to 10 mg ml -1 , incubated at 293 K for 1 hour with a 1.2 M excess of cA4, and centrifuged at 13,000 rpm for 10 minutes prior to crystallization. Sitting drop vapor diffusion experiments were set up at the nanoliter scale using commercially available and in-house crystallization screens and incubated at 293 K. Crystals appeared in various conditions, but those used for data collection grew from 40% 2-methyl-2,4-pentanediol, 5% polyethylene glycol 8000 and 0.1 M sodium cacodylate, pH 6.5. Crystals were harvested and transferred briefly into cryoprotectant containing mother liquor with 20% glycerol immediately before cryo-cooling in liquid nitrogen. The H47A variant was used to avoid cleavage of the cA4 substrate during co-crystallisation. The position of the active site histidine was inferred from the structure of the apo-protein.
Data collection and processing
X-ray data were collected from two crystals at 100 K, at a wavelength 0.9686 Å, on beamline I24 at Diamond Light Source, to 1.49 and 1.60 Å resolution. Both data sets were automatically processed using Xia2 50 , utilizing XDS and XSCALE 51 . The data were merged in Aimless 52 and the overall resolution truncated to 1.55 Å. The data were phased by molecular replacement using Phaser 53 with a monomer from PDB file 2X4I stripped of water molecules as the search model. Model refinement of AcrIII-1 was achieved by iterative cycles of REFMAC5 54 in the CCP4 suite 55 and manual manipulation in COOT 56 . Electron density for cA4 was clearly visible in the maximum likelihood/σA weighted Fobs -Fcalc electron density map at 3s. The coordinates for cA4 were generated in ChemDraw (Perkin Elmer) and the library was generated using acedrg 57 , before fitting of the molecule in COOT. Model quality was monitored throughout using Molprobity 58 . Data and refinement statistics are shown in Table S1 .
Extended dataset
Extended data figure 1. Multiple sequence alignment of DUF1874 family members. Includes the AcrIII-1 proteins from the archaeal viruses SIRV1, STIV, AFV3, ARV1, SIFV, SMV4 and ATV, the integrated conjugative element ICEBs1 protein YddF from B. subtilis, the bacteriophage proteins from Thermoanaerobacterium phageTHSA-485A, Synechococcus phage S-CBWM1, Fusobacterium phage Fnu1, Hydrogenobaculum phage 1 and the Crn2 protein from Crenothrix polyspora. Orthogonal views of SIRV1 gp29 dimer in complex with cA4. The monomers are coloured blue and orange, with catalytic residue H47 from the apo structure shown in salmon. cA4 is shown in green spheres. Conserved residues (Extended data figure 1) in the AcrIII-1 family are indicated and discussed in the text. 
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